This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Radiologic Imaging  • Randomized Controlled Trial  • Magnetic Resonance Imaging  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Integrated 2-Year Results

Frederik Barkhof, MD, PhD; Chris H. Polman, MD, PhD; Ernst-Wilhelm Radue, MD; Ludwig Kappos, MD; Mark S. Freedman, MD; Gilles Edan, MD; Hans-Peter Hartung, MD; David H. Miller, MD; Xavier Montalbán, MD; Peter Poppe, MD; Marlieke de Vos, MSc; Fatiha Lasri, MD; Lars Bauer, MD; Susanne Dahms, PhD; Klaus Wagner, MD; Christoph Pohl, MD; Rupert Sandbrink, MD, PhD

Arch Neurol. 2007;64(9):1292-1298.

Background  In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic resonance imaging (MRI) lesions.

Objective  To examine detailed MRI findings from the first 2 years of this trial.

Design  Double-blind, placebo-controlled, randomized, parallel-group, multicenter, phase 3 study.

Setting  Ninety-eight centers worldwide.

Patients  A total of 404 individuals with a first demyelinating event suggestive of multiple sclerosis.

Interventions  Patients were randomized to receive interferon beta-1b, 250 µg subcutaneously every other day, or placebo. After 24 months of treatment or on conversion to clinically definite multiple sclerosis, open-label interferon beta-1b treatment was offered.

Main Outcome Measures  Reported MRI data from patients completing 2 years of follow-up.

Results  Data were analyzed from 248 patients taking interferon beta-1b and 156 taking placebo. Across 2 years the cumulative number of newly active lesions was lower in patients receiving interferon beta-1b vs placebo (median, 2.0 vs 5.0 [reduction of 60%]; P < .001). This corresponded to lower cumulative numbers of new T2 lesions (median, 1.0 vs 3.0 [reduction of 66%]; P < .001) and new gadolinium-enhancing lesions (median, 0.0 vs 1.0; P < .001) in patients receiving interferon beta-1b vs placebo. From screening to month 24, T2 lesion volume decreased and was more pronounced in patients receiving interferon beta-1b (P = .02).

Conclusions  Interferon beta-1b treatment had a robust effect on MRI measures, supporting its value as an early intervention in this patient group. This effect was maintained despite including patients who switched from placebo to interferon beta-1b in the active treatment group.

Trial Registration  clinicaltrials.gov Identifier: NCT00185211

Author Affiliations: Departments of Diagnostic Radiology (Drs Barkhof, Poppe, and Lasri and Ms de Vos) and Neurology (Dr Polman), Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Department of Neurology and Neurosurgery, University Hospital Basel, Basel, Switzerland (Drs Radue and Kappos); Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Ontario, Canada (Dr Freedman); Department of Neurology, Centre Hospitalier Universitaire, Rennes, France (Dr Edan); Department of Neurology, Heinrich-Heine-Universität, Düsseldorf, Germany (Dr Hartung); Institute of Neurology, University College London, London, England (Dr Miller); Unit of Clinical Neuroimmunology, Hospital Vall d'Hebron, Barcelona, Spain (Dr Montalbán); Bayer Schering Pharma AG, Berlin, Germany (Drs Bauer, Dahms, Wagner, Pohl, and Sandbrink); and Department of Neurology, University Hospital, Bonn, Germany (Dr Pohl).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Moraal et al.
Arch Neurol 2009;66:1345-1352.
ABSTRACT | FULL TEXT  

Subtraction MR Images in a Multiple Sclerosis Multicenter Clinical Trial Setting
Moraal et al.
Radiology 2009;250:506-514.
ABSTRACT | FULL TEXT